LinkedInXFacebook
Subscribe
Orthopedics This Week
  • My Feed
  • |Posts
  • |Events
  • |MSK Innovations
  • |Power Rankings
  • |Masterclasses
  • |Technology Awards
  • Press Releases
  • |Advertising
  • |Job Board
  • Spine
  • ◆Joints
  • ◆Upper Extremities
  • ◆Foot & Ankle
  • ◆Sports Medicine
  • ◆Pain Mgmt
  • ◆Trauma
  • ◆Biologics
  • ◆Technology
  • ◆People
  • ◆Company News
  • ◆Legal & Regulatory
Home/Legal & Regulatory and Reimbursement/Largest FDA Clearance…Ever
Legal & Regulatory and Reimbursement

Largest FDA Clearance…Ever

September 27, 2021 2 min read Premium comments

Advertisement

#tybermedical#fdaclearance#fractureplates

The largest 510(k) FDA clearance in history.

That’s the claim Tyber Medical, LLC makes regarding the August 13, 2021, FDA clearance of the company’s expanded line of anatomical plating systems. The expansion covers all long and short bones.

The clearance, according to the company, has more than 1,500 SKUs (stock keeping units), including over 73 different indication-specific anatomical plating families. The systems were developed using CT scans, clinical data, cadaveric labs, and consultations with orthopedic and podiatric surgeons.

The indication categories for this clearance include Mini-frag/Small Bone, Long Bone Fracture, and Ankle Fracture/Fusion plates.

Mini-frag/Small Bone Plates

The Mini-frag/Small Bone plates, according to the company, incorporate a series of stainless steel and titanium standard and variable locking compression plates and screws of varying lengths, thicknesses, and configurations.

These plates and screws address the “stabilization of fractures, osteotomies, joint fusions, non-unions, and fusions of small bones and small bone fragments to the hand, wrist, foot, and ankle.”

The foot and ankle plating line are used in the fixation of medium/large bones, multi-fragment containment, as well as reconstruction and revision surgeries.

Advertisement

Long Bone Fracture Plates

The Long Bone Fracture plates consist of a straight, low-contact locking plate and a 1/3 locking tubular plate. The company says the plates incorporate hybrid cortical/cancellous thread featuring both variable angle locking and standard non-locking screws.

The plates are intended for osteotomies and non-unions and the fixation of fractures of the clavicle, scapula, olecranon, humerus, radius, ulna, and fibula.

Ankle Fracture/Fusion System

The Ankle Fracture/Fusion System, according to the company, is designed to address a variety of indications in ankle reconstruction mid-shaft and distal tibia/fibula fixation surgery, with a variety of locking plate types for various fibula and tibia positions.

Indications for this system include fixation of fractures of the distal tibia, including ankle fractures, intra-, and extra-articular fractures, osteotomies, medial malleolar fractures, and non-unions of the metaphyseal and diaphyseal region of the distal fibula, and calcaneus; and in distal tibia/fibula long bones.

The specifics of all the cleared indications are available on the FDA web site.

OEM Manufacturer

Advertisement

“Tyber Medical now offers a comprehensive plating solution that bridges different indications and proliferates throughout the entire body to address trauma and deformity to the long and short bones,” said Melissa Coale, Tyber Medical Director of Research & Development.

Company CEO Jeff Tyber said, “It’s been less than 12 months from our first FDA clearance, underscoring the speed at which we can utilize our clinical research to develop, test, and iterate to fill the gaps in our partners’ product portfolios with innovative solutions that benefit patient outcomes.”

Since its founding in 2012, the private labeler original equipment manufacturer (OEM) orthopedic implant maker has released more than 50 extremity/trauma/spine systems. The company says all its products have FDA and CE regulatory clearance. The systems are fully designed, tested, verified, and validated using Tyber Medical’s ISO 13485:2016, EC Certificate and MDASP for the CE Marked Interbody Spacers, and FDA QSR compliant quality system.

React:

Discussion

14
DS
Dr. Sarah MitchellOrthopedic Surgeon · Mayo Clinic

This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?

8
JT
James Thornton, MDSpine Fellow · HSS

Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.

5
RP
R. PatelSports Medicine · Stanford

We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.

Join the conversation

Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.

Subscribe

Get Full Access

Read every OTW article and join member discussions for $24.99/month.

Get Full Access

Advertisement

Advertisement

Advertisement

Orthopedics This Week

The most trusted source in orthopedic industry news since 2005. Covering spine, joints, trauma, biologics, and the business of orthopedics.

A publication of RRY Publications, LLC

LinkedInXFacebook

Categories

  • Spine
  • Joints
  • Upper Extremities
  • Foot & Ankle
  • Sports Medicine
  • Pain Mgmt
  • Trauma
  • Biologics
  • Technology
  • People
  • Company News
  • Legal & Regulatory

Resources

  • Subscribe
  • Community Posts
  • Job Board
  • Press Release Opportunities
  • Power Rankings
  • About OTW
  • Advertise
  • Contact Us

Get Full Access

Unlimited articles, community posts, and Power Rankings.

Get Full Access

Plans start at $24.99/mo · Annual saves 20%

© 2026 Orthopedics This Week · RRY Publications, LLC

Privacy PolicyTerms of ServiceCookie Policy